ARTL
ARTELO BIOSCIENCES, INC.
NASDAQ · Healthcare · Biotechnology · US
$2.23
−3.46%Oct 29, 2026, 13:00 UTC
ARTELO BIOSCIENCES, INC. announced that it will present data on ART27.13’s potential to treat chemotherapy-induced neuropathic pain at the ARTELO BIOSCIENCES, INC..
Source:Oct 26, 2026, 11:55 UTC
ARTELO BIOSCIENCES, INC. plans to showcase its FABP5 inhibitor ART26.12 at the IASP 2026 World Congress on Pain.
Source:Oct 7, 2026, 12:48 UTC
ARTELO BIOSCIENCES, INC. announced that it was selected to make its first company presentation at BIO-Europe 2026, featuring results from the first clinical study of ART26.12 and the potential of its FABP5 inhibitor platform across multiple indications.
Source:Aug 20, 2026, 12:52 UTC
Artelo Biosciences announced that the Japanese Patent Office issued a notice of allowance and Decision to Grant for its patent application covering the intended commercial formulation of ART27.13.
Source:Aug 17, 2026, 12:52 UTC
Artelo Biosciences announced that the U.S. Patent and Trademark Office issued a Notice of Allowance for a patent application covering the intended commercial formulation of ART27.13, expected to extend patent protection through 2041.
Source: